M Christiaans's research while affiliated with Maastricht Universitair Medisch Centrum and other places

... In contrast to most other transplant centers that combine immunosuppressive drugs at decreased doses while keeping their suppressive potential, our transplant center performs rapid steroid removal followed by tacrolimus and mycophenolic acid (MMF) duo therapy for 3 months and thereafter tacrolimus monotherapy. 15,16 In this study, we determined the prevalence and development of D antibodies in recipients who received D-mismatched kidney transplantation in the absence of anti-D prophylaxis and in a transplant setting of reduced immunosuppressive medication. ...

Reference:

The development of D antibodies after D-mismatched kidney transplantation in a setting of reduced immunosuppression

... C u and C bound refers to unbound and bound concentration, respectively [46] introduced a conversion factor as higher concentration in DBS was observed. Although other studies have reported similar findings [15,[47][48][49][50][51], they concluded that the difference between the two methods is still within acceptable limits. Noticeably, since capillary and venous blood are more similar in terms of matrix components, fewer studies reported the use of conversion factor for immunosuppressants as compared with antiepileptics. ...

Reference:

Dried Blood Spots—A Platform for Therapeutic Drug Monitoring (TDM) and Drug/Disease Response Monitoring (DRM)

... 19 Buccal absorption depends on the polarity and lipid solubility of the drug and tacrolimus is a good candidate for sublingual administration due to its high lipophilicity. 54 Even if tacrolimus is administered sublingually, enteral absorption should not be dismissed, 55 as a fraction of the tacrolimus dose may not be readily absorbed in the oral cavity but is ingested and absorbed enterally. 26 Thus, the site of absorption and bioavailability depends on the ability of the swallowing reflex, which is influenced by the sedation status in young children as shown in our study. ...

Reference:

Population pharmacokinetics of sublingually administered tacrolimus in infants and young children with liver transplantation

... These stimuli commonly reverse LPS tolerance and/or train/prime macrophages through epigenetic reprogramming. One of the key epigenetic mechanisms in reversing tolerance is mediated by introducing/stabilizing the transactivation histone markers, namely H3K4me2/3 and H3K27ac, or removing the silencing histone marker H3K9me2/3 [10,46,47]. These histone modifications at the promoters and enhancers are introduced in response to training stimuli in a gene-specific manner. ...

Reference:

Prolonged Inhibition of the MEK1/2-ERK Signaling Axis Primes Interleukin-1 Beta Expression through Histone 3 Lysine 9 Demethylation in Murine Macrophages

... In kidney transplantation, some retrospective studies with large cohorts identified an increased risk of graft failure in female recipients of kidneys from male donors compared to the rest of the possible gender combinations [94][95][96][97]. On the other hand, a large retrospective study of simultaneous pancreas-renal transplantation found that graft survival was not influenced by different gender combinations, nor were there differences in the survival of each individual graft [98]. ...

Reference:

Non-HLA Abs in Solid Organ Transplantation

... Amongst them, sublingual (SL) administration has been reported in six studies since 2001. [6][7][8][9][10][11][12] However, most were small, uncontrolled retrospective studies and did not evaluate the total exposure to tacrolimus. One of these studies included liver transplant recipients, although it included only six patients. ...

Reference:

Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study

... The stability of DBS samples has been investigated by various studies as presented in Tables 1, 2, 3, 4, 5 and 6. Heijden et al. demonstrated that everolimus is stable for 3 days in the mailbox at 60 °C and 32 days at 4 °C [80]. Hoogtanders et al., meanwhile, investigated the stability of DBS in postal transport by measuring drug concentration immediately after sampling and in a duplicate sample sent by the patient from home by mail [81]. ...

Reference:

Dried Blood Spots—A Platform for Therapeutic Drug Monitoring (TDM) and Drug/Disease Response Monitoring (DRM)

... In this study, we found that increases in HLA class II matching had a significant effect on graft rejection episodes at early times after transplantation. This confirms the findings of other studies in both renal and heart transplant recipients that have found that HLA-DR mismatching is associated with an increased frequency and severity of graft rejection (12,13,21,(25)(26)(27)(28) as well a shortened time to development of the first acute rejection episode (13). Moreover, we found that matching for the HLA-B locus but not the HLA-A locus significantly reduced the number of late graft rejection episodes and improved graft function at 1 and 2 years after transplantation. ...

Reference:

Matching for private or public HLA epitopes reduce acute rejection episodes and improves tow year renal allograft function

... Definitive proof requires cessation of the drug and normalization of white cell count [11]. Tacrolimus administration along with MMF increases area under curve for MMF gradually over 3 month by 20-30% [170]. Keeping these studies in mind, many studies conducted in Asian renal transplant recipients, including a randomized controlled trial, suggested the need for MMF dose reduction in patients with tacrolimus to minimize the side effects of MMF including myelotoxicity [171][172][173]. ...

Reference:

Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians

... We also found C 0 / Dose of POR*1/*1 carriers was higher than POR*28 carriers, especially for recipients at 7 days post-transplantations. Numerous studies conducted in adults have documented a reduction in the necessary dosage of tacrolimus to achieve comparable trough concentrations as time progresses post-transplant [42][43][44][45]. The decline in tacrolimus clearance over time is typically attributed as the primary factor, although heightened bioavailability should also be taken into consideration [46]. ...

Reference:

Effects of CYP3A4*22 and POR*28 variations on the pharmacokinetics of tacrolimus in renal transplant recipients: a meta-analysis of 18 observational studies